Welcome to our dedicated page for Kkr & Co news (Ticker: KKR), a resource for investors and traders seeking the latest updates and insights on Kkr & Co stock.
KKR & Co Inc (KKR) is a leading global alternative asset manager with a 45+ year track record in private equity, credit, and infrastructure investments. This page provides investors and financial professionals with timely access to official press releases, earnings reports, and strategic updates directly from KKR.
Key resources include: Quarterly earnings announcements, merger & acquisition disclosures, leadership updates, and partnership developments. Our curated feed ensures you stay informed about KKR's global initiatives across private markets, real estate, and insurance solutions through Global Atlantic Financial Group.
Bookmark this page for verified updates on KKR's investment activities, ESG commitments, and capital allocation strategies. All content is sourced from official company communications to ensure accuracy and compliance with financial disclosure standards.
KKR (NYSE:KKR) has announced an agreement to sell its controlling stake in J.B. Chemicals & Pharmaceuticals (JB Pharma) to Torrent Pharmaceuticals in a significant two-phase transaction valued at INR 25,689 crores (on fully diluted basis).
The transaction structure includes: 1) Acquisition of 46.39% equity stake through a Share Purchase Agreement at INR 11,917 crores (INR 1,600 per share), followed by a mandatory open offer for up to 26% additional shares at INR 1,639.18 per share. 2) Merger between Torrent and JB Pharma where shareholders will receive 51 Torrent shares for every 100 JB Pharma shares.
The strategic acquisition strengthens Torrent's presence in the Indian pharmaceutical market, particularly in chronic segments, while providing entry into new areas like ophthalmology and CDMO capabilities. The deal requires approvals from various regulatory bodies including SEBI, Stock Exchanges, CCI, and NCLT.